Respiratory News and Research

RSS

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Today Biogen Idec announced that Health Canada has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with hemophilia B.

21 Mar 2014

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

Genzyme, a Sanofi company, announced today that Brazil's national health surveillance agency, ANVISA, has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS) to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations.

21 Mar 2014

Research roundup: New medical coding system; choosing a hospice; revamping Medicare

On October 1, 2014, all health plans, health data clearinghouses, and health care providers that transmit health information electronically must use a new, significantly broader, coding system, called ICD-10, for diagnoses and inpatient procedures.

21 Mar 2014

China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the year ended December 31, 2013.

21 Mar 2014

Concordia Healthcare enters into definitive agreement to acquire Donnatal

Concordia Healthcare Corp., announced today that it has entered into a definitive agreement to acquire Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS") and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals").

20 Mar 2014

Tamiflu cuts H1N1 pandemic deaths by 25%, shows study

Adults hospitalised with H1N1 influenza during the 2009–2010 pandemic were 25% less likely to die from the disease if they were given antiviral drugs called neuraminidase inhibitors (NAIs) such as Tamiflu, according to a large meta-analysis involving more than 29 000 patients from 38 countries, published in The Lancet Respiratory Medicine journal. The findings also indicate that treatment within 2 days of flu symptoms developing halved the risk of death compared with later treatment or no treatment.

20 Mar 2014

Researchers evaluate exposure to snuff smoke in nonsmokers after launch of second law

Researchers of the Tobaco Control Unit of the Catalan Institute of Oncology (ICO) and the Bellvitge Biomedical Research Institute (IDIBELL) evaluated exposure to snuff smoke in nonsmokers before the entry into force of the first Spanish smoking ban and after the launch of the second law (2011 ) in the city of Barcelona.

19 Mar 2014

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Amgen (NASDAQ: AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab met its primary endpoint of the percent reduction from baseline at week 12 in low-density lipoprotein cholesterol (LDL-C).

19 Mar 2014

Lung ultrasound could help determine if pregnant woman with preeclampsia is at risk for respiratory failure

18 Mar 2014

Body clock's could be utilized to improve current therapies to delay onset of chronic lung diseases

The body clock's natural rhythm could be utilized to improve current therapies to delay the onset of chronic lung diseases.

From The University of Manchester 18 Mar 2014

ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension.

18 Mar 2014

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy".

18 Mar 2014

S. pneumoniae thrives in human saliva

Streptococcus pneumoniae is able to survive and thrive in human saliva, Dutch researchers have shown.

17 Mar 2014

Study shows only 23% of seasonal and pandemic flu caused symptoms

Around 1 in 5 of the population were infected in both recent outbreaks of seasonal flu and the 2009 H1N1 influenza pandemic, but just 23% of these infections caused symptoms, and only 17% of people were ill enough to consult their doctor.

17 Mar 2014

L. reuteri Protectis reduces diarrhea, respiratory tract infections in healthy children

Healthy children attending day-care centres have a significantly lower risk of getting diarrhoea or respiratory tract infections when given a daily supplement of Lactobacillus reuteri Protectis, a study in 336 children shows. "Our study confirms earlier published data in proving that preventive use of L. reuteri Protectis in healthy children reduces diarrhoeic episodes.

17 Mar 2014

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

Edison Pharmaceuticals today announced the initiation of a phase 2 study entitled "A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone™) in Children with Pearson Syndrome." The Investigative New Drug application (IND) was approved by the Food and Drug Administration, Office of Hematology and Oncology Products.

17 Mar 2014

FDA grants Fast Track designation to Edison’s lead drug EPI-743

Edison Pharmaceuticals today announced that the United States Food and Drug Administration granted Fast Track designation to EPI-743, the company's lead drug, for the treatment of Friedreich's ataxia. EPI-743 is being developed for pediatric and adult mitochondrial disease, including Friedreich's ataxia.

17 Mar 2014

Respiratory News and Research

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

Research roundup: New medical coding system; choosing a hospice; revamping Medicare

China Pharma Holdings' revenue decreases 40% to $32.8 million in fiscal year 2013

Concordia Healthcare enters into definitive agreement to acquire Donnatal

Tamiflu cuts H1N1 pandemic deaths by 25%, shows study

Researchers evaluate exposure to snuff smoke in nonsmokers after launch of second law

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Lung ultrasound could help determine if pregnant woman with preeclampsia is at risk for respiratory failure

Body clock's could be utilized to improve current therapies to delay onset of chronic lung diseases

ATS develops clinical practice guidelines to help clinicians identify, manage patients with sickle cell disease

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

S. pneumoniae thrives in human saliva

Study shows only 23% of seasonal and pandemic flu caused symptoms

L. reuteri Protectis reduces diarrhea, respiratory tract infections in healthy children

Edison Pharmaceuticals begins EPI-743 clinical trial in children with Pearson syndrome

FDA grants Fast Track designation to Edison’s lead drug EPI-743

Discovery Laboratories reports net loss of $11.7 million for fourth quarter 2013

Aradigm reports record revenue of $4.6M in fourth quarter 2013

CRO services division of Galapagos to be acquired by Charles River Laboratories

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News